{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T02:12:58Z","timestamp":1774404778114,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":550,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1124\/jpet.122.001368","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T15:05:21Z","timestamp":1681743921000},"page":"26-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Nonclinical Cardiovascular Assessment of the Soluble Guanylate Cyclase Stimulator Vericiguat"],"prefix":"10.1016","volume":"386","author":[{"given":"Herbert","family":"Himmel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"Lagrutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"V\u00f6mel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupesh P.","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Imredy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya","family":"Vinzing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Prescott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert O.","family":"Blaustein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 6","key":"10.1124\/jpet.122.001368_bib1","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.jelectrocard.2007.05.020","article-title":"Regulation of ion channels and arrhythmias in the ischemic heart","volume":"40","author":"Akar","year":"2007","journal-title":"J Electrocardiol"},{"key":"10.1124\/jpet.122.001368_bib2","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001368_bib3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00005344-199424020-00003","article-title":"Comparative effects of increased extracellular potassium and pacing frequency on the class III activities of methanesulfonanilide IKr blockers dofetilide, D-sotalol, E-4031, and MK-499","volume":"24","author":"Baskin","year":"1994","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/jpet.122.001368_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/ehaa946.3328","article-title":"Vericiguat clinical pharmacology programme: biopharmaceutical properties and potential intrinsic and extrinsic factor effects","volume":"41","author":"Boettcher","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1124\/jpet.122.001368_bib5","article-title":"Vericiguat: a QTc interval study in patients with coronary artery disease","author":"Boettcher","year":"2021","journal-title":"ESC 2021"},{"key":"10.1124\/jpet.122.001368_bib6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s13300-011-0003-2","article-title":"Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT\/QTc study","volume":"2","author":"Carlson","year":"2011","journal-title":"Diabetes Ther"},{"key":"10.1124\/jpet.122.001368_bib7","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1152\/physrev.1999.79.3.917","article-title":"Cardiac ionic currents and acute ischemia: from channels to arrhythmias","volume":"79","author":"Carmeliet","year":"1999","journal-title":"Physiol Rev"},{"key":"10.1124\/jpet.122.001368_bib34","unstructured":"Center for Drug Evaluation and Research (2021) Risk assessment and risk mitigation review(s). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/214377Orig1s000RiskR.pdf. Accessed October 21, 2021."},{"key":"10.1124\/jpet.122.001368_bib8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0022-3565(24)35285-1","article-title":"Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions","volume":"292","author":"Crumb","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001368_bib9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.vascn.2016.03.009","article-title":"An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel","volume":"81","author":"Crumb","year":"2016","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1124\/jpet.122.001368_bib10","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s13300-018-0442-0","article-title":"No QTc prolongation with semaglutide: a thorough QT study in healthy subjects","volume":"9","author":"Demmel","year":"2018","journal-title":"Diabetes Ther"},{"key":"10.1124\/jpet.122.001368_bib11","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1161\/01.CIR.94.7.1592","article-title":"Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans","volume":"94","author":"D\u00e9molis","year":"1996","journal-title":"Circulation"},{"key":"10.1124\/jpet.122.001368_bib45","unstructured":"European Medicines Agency (2005) ICH topic E14. The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e-14-clinical-evaluationqt\/qtsinterval-prolongation-proarrhythmic-potential-non-antiarrhythmic-drugs-step-5_en.pdf. Accessed December 01, 2022."},{"key":"10.1124\/jpet.122.001368_bib44","unstructured":"European Medicines Agency (2006) ICH Topic S7B The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. https:\/\/www.ema.europa.eu\/en\/documents\/scientificguideline\/ich-s-7-b-nonclinical-evaluationpotential-delayed-ventricular-repolarization-qtinterval_en.pdf Accessed December 01, 2022."},{"key":"10.1124\/jpet.122.001368_bib43","unstructured":"European Medicines Agency (2013) ICH M3 (R2) Non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-m3r2-nonclinicalsafety-studies-conduct- human-clinical-trials-marketing-authorisation_en.pdf. Accessed December 01, 2022."},{"key":"10.1124\/jpet.122.001368_bib41","unstructured":"European Medicines Agency (2020) ICH guideline E14\/S7B on clinical and nonclinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential questions & answers. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ichguidelinee14\/s7b-clinical-nonclinical-evaluation-qt\/qtc-interval-prolongation-proarrhythmicpotentialquestions-answers-step-2b_en.pdf. Accessed December 01, 2022."},{"key":"10.1124\/jpet.122.001368_bib42","unstructured":"European Medicines Agency (2021) Verquvo TM Summary of opinion (initial authorisation). https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positiveopinionverquvo_en.pdf. Accessed December 01, 2022."},{"key":"10.1124\/jpet.122.001368_bib40","unstructured":"Food and Drug Administration (2021) Verquvo TM (vericiguat) tablets. Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214377s000lbl.pdf. Accessed May 11, 2022."},{"key":"10.1124\/jpet.122.001368_bib12","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.0954-6820.1920.tb18266.x","article-title":"Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken","volume":"53","author":"Fridericia","year":"1920","journal-title":"Acta Med Scand"},{"key":"10.1124\/jpet.122.001368_bib13","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1161\/01.CIR.0000100721.52503.85","article-title":"Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study","volume":"108","author":"Grimm","year":"2003","journal-title":"Circulation"},{"key":"10.1124\/jpet.122.001368_bib14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1161\/CIRCULATIONAHA.116.027134","article-title":"Personalizing risk stratification for sudden death in dilated cardiomyopathy: the past, present, and future","volume":"136","author":"Halliday","year":"2017","journal-title":"Circulation"},{"key":"10.1124\/jpet.122.001368_bib15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/eurjhf\/hfs010","article-title":"Profile of microvolt T-wave alternans testing in 1003 patients hospitalized with heart failure","volume":"14","author":"Jackson","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1124\/jpet.122.001368_bib16","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00228-016-2062-9","article-title":"Single therapeutic and supratherapeutic doses of sacubitril\/valsartan (LCZ696) do not affect cardiac repolarization","volume":"72","author":"Langenickel","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/jpet.122.001368_bib17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.amjcard.2020.04.051","article-title":"Electrolyte abnormalities in patients presenting with ventricular arrhythmia (from the LYTE-VT Study)","volume":"129","author":"Laslett","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1124\/jpet.122.001368_bib18","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/cpdd.1003","article-title":"Update on ICH E14\/S7B cardiac safety regulations: the expanded role of preclinical assays and the \u201cdouble-negative\u201d scenario","volume":"10","author":"Lester","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1124\/jpet.122.001368_bib19","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.116.004628","article-title":"Improving the in silico assessment of proarrhythmia risk by combining hERG (human Ether-\u00e0-go-go-Related Gene) channel-drug binding kinetics and multichannel pharmacology","volume":"10","author":"Li","year":"2017","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1124\/jpet.122.001368_bib20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1056-8719(97)00098-1","article-title":"QT corrected for heart rate and relation between QT and RR intervals in beagle dogs","volume":"38","author":"Matsunaga","year":"1997","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1124\/jpet.122.001368_bib21","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1124\/jpet.122.001368_bib22","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1161\/CIRCRESAHA.116.309396","article-title":"Dilated cardiomyopathy: genetic determinants and mechanisms","volume":"121","author":"McNally","year":"2017","journal-title":"Circ Res"},{"key":"10.1124\/jpet.122.001368_bib23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11897-013-0171-7","article-title":"Arrhythmia risk associated with sleep disordered breathing in chronic heart failure","volume":"11","author":"Mehra","year":"2014","journal-title":"Curr Heart Fail Rep"},{"key":"10.1124\/jpet.122.001368_bib24","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1046\/j.1540-8167.2004.03428.x","article-title":"Enhanced detection of arrhythmia vulnerability using T wave alternans, left ventricular ejection fraction, and programmed ventricular stimulation: a prospective study in subjects with chronic ischemic heart disease","volume":"15","author":"Rashba","year":"2004","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1124\/jpet.122.001368_bib25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovasc Res"},{"key":"10.1124\/jpet.122.001368_bib26","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/01.RES.80.1.124","article-title":"Electrophysiologic effects of acute myocardial ischemia. A mechanistic investigation of action potential conduction and conduction failure","volume":"80","author":"Shaw","year":"1997","journal-title":"Circ Res"},{"key":"10.1124\/jpet.122.001368_bib27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.vascn.2010.05.011","article-title":"Cardiovascular safety assessments in the conscious telemetered dog: utilisation of super-intervals to enhance statistical power","volume":"62","author":"Sivarajah","year":"2010","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1124\/jpet.122.001368_bib28","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1124\/dmd.118.080515","article-title":"Safety assessment of acyl glucuronides\u2014a simplified paradigm","volume":"46","author":"Smith","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.122.001368_bib29","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","article-title":"Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease","volume":"123","author":"Stasch","year":"2011","journal-title":"Circulation"},{"key":"10.1124\/jpet.122.001368_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2020.109881","article-title":"Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: results from a phase 1 QT\/QTc study","volume":"100","author":"Sun","year":"2020","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1124\/jpet.122.001368_bib31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0160-5402(89)90015-6","article-title":"An improved method to correct the QT interval of the electrocardiogram for changes in heart rate","volume":"22","author":"Van de Water","year":"1989","journal-title":"J Pharmacol Methods"},{"issue":"Suppl 1","key":"10.1124\/jpet.122.001368_bib32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s003950050236","article-title":"Rate-dependence of antiarrhythmic and proarrhythmic properties of class I and class III antiarrhythmic drugs","volume":"93","author":"Weirich","year":"1998","journal-title":"Basic Res Cardiol"},{"key":"10.1124\/jpet.122.001368_bib33","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0006-3495(98)77782-3","article-title":"Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature","volume":"74","author":"Zhou","year":"1998","journal-title":"Biophys J"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524170437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524170437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.122.001368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:29:28Z","timestamp":1739971768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524170437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0022356524170437"],"URL":"https:\/\/doi.org\/10.1124\/jpet.122.001368","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonclinical Cardiovascular Assessment of the Soluble Guanylate Cyclase Stimulator Vericiguat","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.122.001368","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The Author(s)","name":"copyright","label":"Copyright"}]}}